USPTO serial 98975541
STRIVE
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- GERMICK JR., EDWARD JOSEPH
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with STRIVE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $125
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Parsippany, NJ, US
Parsippany, NJ, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
STEPHEN R. BAIRD
Stephen R. Baird GREENBERG TRAURIG, LLP90 SOUTH SEVENTH STREET, SUITE 3500MINNEAPOLIS, MN 55402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Medical devices and apparatus in the field of diabetes, namely, medical devices and apparatus for measuring blood glucose levels and injecting insulin; Medical devices and medical apparatus in the field of diabetes, namely, medical devices for monitoring blood glucose levels and administering insulin therapy; Medical devices, namely, diabetes management devices in the nature of insulin pumps, blood glucose monitors, infusion pumps, infusion pump controllers and structural and replacement parts therefor; Medical devices and medical apparatus in the field of diabetes, namely, patch pumps for administering continuous subcutaneous insulin infusion for insulin therapy; Medical devices and medical apparatus in the field of diabetes, namely, wearable subcutaneous drug delivery devices, sold empty, in the nature of on-body injectors, insulin injectors, infusion pumps, insulin pumps, patch pumps, and controllers, and structural and replacement parts therefor; Medical venous access ports; lancets; needles for medical use; syringes for medical use; Pen needles used to deliver medications to manage diabetes; Infusion sets; Infusion pump accessories, namely, belt clips specifically designed for holding infusion pumps and infusion sets; Subcutaneous infusion sets for use by diabetes patients in connection with insulin pumps; Infusion pumps; Insulin pumps; Infusion and insulin pump accessories, namely, medical sensors, meters, and medical devices for measuring and monitoring blood and urine properties; Medical devices and medical apparatus for measuring and monitoring blood and urine properties; Glucose meters; Blood glucose meters; Medical apparatus for monitoring blood glucose levels; Medical apparatus and instruments for monitoring glucose; Continuous glucose monitoring systems comprised of a medical apparatus for monitoring glucose; Sensor-based glucose monitors for medical purposes; Blood glucose monitoring systems, namely, blood glucose monitors, and parts and accessories therefor, namely, blood glucose monitoring carrying cases, and electronic blood glucose test diaries in the nature of integrated computer memory devices within blood glucose monitors; Devices for monitoring blood glucose for medical purposes; Devices for measuring blood sugar; Medical devices, namely, medical sensors that are implanted and inserted into the human body used to continuously monitor the concentration of glucose in the human body and accessories therefor, namely, data receivers, sensor housings and sensor insertion devices; Medical diagnostic apparatus for testing blood sugar levels incorporating recorded software for the collection, editing, organizing, modifying, transmission, storage and sharing of medical information; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for collecting, presenting, controlling, analyzing, reporting, storing, transmitting and managing medical information, patient information, patient care information and information about tracking the medicines of patients; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for controlling and managing patient medical information; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for collecting, editing, organizing, modifying, transmitting, storing, and sharing patient care instructions and medical information; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for acquiring, analyzing, transmitting and storing medical and physiological data; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for viewing, sharing, reporting, maintaining, managing, monitoring, and analyzing data and information in the fields of nutrition, health and wellness, and diabetes treatment and management; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for collection, presentation, control, analysis, reporting, storage, transmission and management of data for use in the field of digital therapeutics; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for use in the treatment and management of diabetes; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for linking medical instruments and devices for use in the treatment and management of diabetes; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for collecting, editing, organizing, modifying, transmitting, storing, and sharing patient care instructions and medical information for providing nonmedical interventions, namely, alerts about blood glucose levels, physical activity, injections, and medication adherence for individuals in the treatment and management of diabetes; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for collecting, editing, organizing, modifying, transmitting, storing, and sharing patient care instructions and medical information for preparing and delivering reports and analytics relating to medical and physiological data in the treatment and management of diabetes; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of blood glucose monitors incorporating computer hardware and recorded software for monitoring blood glucose in connection with blood glucose monitors; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of insulin pumps incorporating computer hardware and recorded software for controlling insulin delivery in connection with insulin pumps; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for capturing, storing, processing, controlling, analyzing, managing, tracking, monitoring, and transmitting patient medical data from medical devices, namely, wearable medical devices, insulin pumps, and blood glucose monitors; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for obtaining, controlling, and managing patient medical information on wearable medical devices; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software for controlling and managing wearable insulin delivery devices; Medical devices and apparatus in the field of diabetes, namely, diabetes management devices in the nature of infusion pumps, insulin pumps, and blood glucose monitors incorporating computer hardware and recorded software used to display, manage, and monitor diabetes management information | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 28, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 3, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 3, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 25, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 9, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 9, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 9, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 9, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 9, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 2, 2026 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 28, 2025 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Oct 3, 2025 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Oct 2, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 22, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 22, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 22, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 22, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 16, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 16, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 16, 2025 | ALIE | ASSIGNED TO LIE | — |
| Sep 5, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Sep 5, 2025 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Sep 5, 2025 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Sep 5, 2025 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| May 30, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| May 30, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Mar 8, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 8, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 8, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 12, 2025 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Feb 12, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 5, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 5, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 5, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 4, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jun 4, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| May 16, 2024 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| May 16, 2024 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Mar 5, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 5, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 5, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 1, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 16, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 21, 2023 | NWAP | NEW APPLICATION ENTERED | — |